For more than 50 years, Besins Healthcare has discovered, developed and delivered healthcare solutions to help women successfully manage the often unexpected issues related to the transition through menopause. Our products are prescribed by physicians in more than 100 countries worldwide.
Globally we are a major player in Menopause Hormone Therapy (MHT), having developed a transdermal estradiol gel, Estrogel®, and a micronised natural progesterone in an oily formulation (Prometrium®), bioavailable by oral route of administration. In 2016 we made Prometrium, micronised progesterone, available in Australia for menopause hormone therapy in women; along with Utrogestan®, micronised progesterone, for luteal phase support in ART.
In 2014, Besins Healthcare Australia resumed responsibility for Testogel®, a therapy developed and introduced by our company for hypogonadism.
Besins remains committed to discovering additional innovations in menopause, gynaecology, fertility and obstetrics. In 2019 we are proud to be able to expand our MHT range of products for Australian women transitioning through menopause.